Phase 2 N=46 Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=25 Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Primary: Correlation of Tumor-informed CAPP-Seq ctDNA Analysis With Radiologic Tumor Assessments — 100; 66; 100; NA Percent Accuracy
Phase 2 N=811 An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC
Non-Small Cell Lung Cancer
Primary: Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events — 1; 7; 0; 1 Participants
Phase 3 N=1,093 First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin
Non Small Cell Lung Cancer
Primary: Overall Survival Time (OS) — 11.5; 9.9 Months — p=0.0120
Phase 3 N=633 First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin
Non Small Cell Lung Cancer
Primary: Overall Survival Time (OS) — 11.3; 11.5 Months — p=0.9561
Phase 4 N=109 A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) During the Induction and Maintenance Therapy Periods — 5.6 months
Phase 3 N=939 A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Overall Survival — 12.55; 13.40 months — p=0.94896
Phase 3 N=598 Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Overall Survival — 26.81; 24.97 months — p=0.831
Phase 2 N=172 A Study in Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Progression-free Survival (PFS) — 5.45; 5.22 months — p=0.848
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Phase 2 N=42 Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
Lung Cancer
Primary: PERCIST Partial Metabolic Response — 6 participants
Phase 2 N=54 A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
Primary: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) — 51.0 percentage of…
Phase 3 N=357 Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC
Squamous NSCLC
Primary: PFS(Progression Free Survival) — 5.5; 4.9 months
N/A N=29 Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Phase 3 N=572 A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) in the TC3 or IC3-WT Populations — 13.1; 20.2 Months — p=0.0106
Phase 2 N=76 A Study in Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Phase 2: Progression-Free Survival Time — 4.7; 1.5 months
Phase 2 N=192 A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Squamous Non-small Cell Lung Cancer
Primary: Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0 Participants
Phase 2 N=247 A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer
Non-Small-Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 7.4; 3.8; 4.4 months — p=0.003
Phase 2 N=70 Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers
Non-small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 9.95; 6.83 Months — p=0.0618
Phase 2 N=159 A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer Stage IV
Primary: Progression Free Survival (PFS) — 2.53; 4.21 months — p=0.0068
Phase 2 N=46 Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients
Non Small Cell Lung Cancer
Primary: Progression Free Survival — 77.1 percentage of participants
Phase 2 N=113 A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer
Non-Small-Cell Lung Cancer
Primary: Percentage of Participants With a Tumor Response (Objective Tumor Response Rate) — 38.5 percentage of participants
Phase 2 N=71 Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: The Primary Goal of This Study is to Show That the Addition of Bevacizumab to Cisplatin-based Chemotherapy in the Neoadjuvant Setting for Non-squamous Cell Carcinomas…
Phase 3 N=939 A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Investigator-assessed Objective Progression-free Survival (PFS) — 4.11; 2.83 months — p=0.00006
Phase 2 N=105 Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) at 18-month — 65.5; 66.3 Percentage of participants
Phase 2 N=11 LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
N/A N=200 A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
Squamous Non-small Cell Lung Cancer
Primary: Time on Treatment With Afatinib or Chemotherapy During Second Line (2L) Treatment — 7.3; 4.2 months
Phase 2 N=38 Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung (NSCLC)
Primary: Percentage of Participants With Objective Response (OR) — 39.5 Percentage of participants
Phase 3 N=98 Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Recurrent Squamous Cell Lung Carcinoma · Stage IV Squamous Cell Lung Carcinoma AJCC v7
Primary: Response Rate in MEDI4736-treated Participants — 16 percentage of participants
Phase 2 N=63 Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) Rate as Per Investigator Local Review Measured Using RECIST 1.1 of Patients at Week 12 — 23.3; 20.0 Percentage of participants